期刊文献+

血清脂质结合唾液酸、组织多肽抗原、组织蛋白酶、卵巢癌抗原X1及CA125联合检测对卵巢上皮性癌的诊断价值 被引量:10

The early diagnosis of joint detection LASA,TPA,CATL,OVX1 and CA125 in patients with epithelial ovarian cancer
原文传递
导出
摘要 目的探讨血清脂质结合唾液酸(LASA)、组织多肽抗原(TPA)、组织蛋白酶(CATL)、卵巢癌抗原X1(OVX1)及CA125联检对卵巢上皮性癌(EOC)的早期诊断价值。方法选择2007年8月至2010年11月兰州大学第二医院和兰州市第一人民医院妇产科拟行手术治疗的卵巢上皮性癌患者86例及良性上皮性卵巢肿瘤患者100例、健康对照组50例,测定其LASA、TPA、CATL、OVX1血清水平。并收集相应卵巢肿瘤患者的临床资料,分析其CA125水平。结果 5项指标恶性组均明显高于良性组和健康对照组(P均<0.05)。TPA对EOC的总阳性率以及早期检测阳性率均最高,LASA和OVX1对EOC的总阳性率均低于CA125,CATL对EOC的总阳性率略高于CA125,但是对EOC早期检测阳性率均高于CA125。CA125+TPA对EOC的总阳性率以及早期检测阳性率也均为最高;余3项指标与CA125两两联合检测时对EOC早期检测阳性率均明显高于CA125单检(P均<0.05),对EOC的总阳性率均明显高于CA125单检,除CA125+OVX1与CA125单检时差异无统计学意义外,其余差异均有统计学意义(P均<0.05)。结论血清LASA、TPA、CATL及OVX1是具有潜力的EOC诊断指标,TPA和CA125联检是理想的组合方式,兼顾了对EOC的总阳性率以及早期检测阳性率,提高了对EOC的诊断率。 Objective To study the diagnostic value of combined determination of serum CA125, LASA,TpA, CATL and OVX1 in patients with early stage EOC. Methods EOC group 86,the benign epithelial ovarian tumor group 100 and healthy women group 50 of Lanzhou University Second Hospital and First Hospital of Lanzhou between 2007 and 2010 ;Serum levels of LASA, TPA, CATL and OVX1 were ascertained by enzyme-linked immunosorbent assay (ELISA) o The clinical data of the corresponding period patients with ovarian tumor were collected to analyze the serum level of CA125. Results The serum levels of CA125 ,LASA,TPA,CATL and OVX1 in EOC group were significantly higher than the benign epithelial ovarian tumor group and healthy women group (P 〈 0. 05, respectively). In single test, the total posi- tive rate and early diagnosis rate of TPA for EOC are highest;the total positive rate of LASA and OVX1 are inferior to CA125 ,the total positive rate of CATL are slightly above CA125, but the early diagnosis rate of others are higher than CA125. In the joint test ,the total positive rate and early diagnosis rate of TPA plus CA125 for EOC are highest,the early diagnosis rate of others joint with CA125 are higher than CA125 single (P 〈 0. 05, respectively), the total positive rate for EOC are higher than CA125 single(P 〈 0. 05, respectively), except CA125 plus OVX1 . Conclusion The serum levels of CA125 ,LASA ,TPA, CATL and OVX1 all could be used as the important tumor markers of EOC, CA125 and TPA together is the best ,can improve the total positive rate ,early diagnosis rate and the diagnosis rate of EOC.
作者 李惠新 李晶
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2012年第12期942-944,共3页 Chinese Journal of Practical Gynecology and Obstetrics
  • 相关文献

参考文献7

二级参考文献39

  • 1陈卫中,倪宗瓒,潘晓平,刘元元,夏彦.用ROC曲线确定最佳临界点和可疑值范围[J].现代预防医学,2005,32(7):729-731. 被引量:208
  • 2刘勇,李芙泉,王嘉嘉,苏晨,程细祥.蛋白芯片检测多肿瘤标志物及对三种癌症的诊断价值[J].标记免疫分析与临床,2005,12(2):100-103. 被引量:9
  • 3翁彬,孟庆宝,王雷萍,段纯.肿瘤标志物联合检测诊断卵巢癌的实验研究[J].医学临床研究,2006,23(4):486-487. 被引量:17
  • 4王兰君,李国兴,王秀民.卵巢癌和胰腺癌患者血清CA125、CA199的水平相关分析[J].放射免疫学杂志,2007,20(1):68-69. 被引量:6
  • 5陈平雁.SPSS13.0统计软件应用教程[M].第1版.北京:人民卫生出版社.2006.322-326.
  • 6Meier W, Baumgartmer L, Stieber P, et al. CA125 based diagnosis and therapy in recurrent ovarian cancer [J]. Anticancer Res, 1997, 17: 3019-3020.
  • 7Mills GB, Bast RC Jr, Srivastava S. Future for ovarian cancer screening novel markers from emerging technologies of transcriptional profiling and proteomics [J]. Journal of the National Cancer Institute, 2001, 93: 1458-1464.
  • 8Gadducci A, Ferdeghini M, Pronteva C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses : relevance for differential diagnosis[J]. Gyneol Oncol, 1992, 44: 147-154.
  • 9Jemal A, Tiwarl RC, Murray T, et al. American Cancer Society : Cancer statistics,2004 [J]. CA Cancer J Clin,2004,54:8 - 29.
  • 10Drapkln R, Heeht JL. The origins of ovarian cancer: hurdles and progress[ J]. Women's Oncol Rev,2002 ,2 :261 - 268.

共引文献33

同被引文献85

  • 1李斌,卢景琛,罗建远,刘祺,贺玉香.血清CEA、CA199表达与胃癌细胞浸润转移的相关性研究[J].实用肿瘤杂志,2007,22(4):321-323. 被引量:21
  • 2Buys SS, PamSdge E, Black A, et al. Effect of screening on ovari- an cancer mortality : the prostate, lung, colorectal and ovarian ( PL- CO) cancer screening randomized controlled trial [ J]. JAMA, 2011,305 ( 22 ) : 2295-2303.
  • 3Brown PO, Palmer C. The preclinical natural history of serous o- varian cancer: defining the target for early detection [ J ]. PLoS Med ,2009,6 (7) : elO00114.
  • 4Galgano MT, Hampton GM, Frierson HFJr, et al. Comprehensive analysis of HE4 expression in normal and malignant human tis- sues [ J 1. Mod Patho1,2006,19 (6) : 847-853.
  • 5Moore RG, MeMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of o- varian cancer in patients with a pelvic mass [ J ]. Gynecol Oncol, 2009,112 ( 1 ) :40-46.
  • 6Sedlrkova I, Vrvrov J, Tosner J, et al. Lysophosphatidic acid in ovarian caneer patients [ J ]. Ceska Gyriekol, 2006,71 ( 4 ) : 312- 317.
  • 7Barbieri RL. In women who have a pelvic mass Have youtried this new ovarian Ca biomarker[J].OBG Management,2010,22 (4) : 8-12.
  • 8Diefenbach CS, Shah Z, lasonos A, et al. Preoperative serum YKL- 40 is a marker for detection and prognosis of endometrial cancerl[J]. Gynecol Oneol,2007,104(2) :435-442.
  • 9Hogdall EV, Johansen JS, Kjaer SK, et al. High plasma "YKL-d0 level in patients with ovarian cancer stage 111 is related to shorter survival[J]. Oncol Rep,2009,10(5) :1535-1538.
  • 10Ramus SJ, Kartsonaki C, Gayther SA, et al. Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers[J]. J Natl Cancer Inst,2011,103 (2):105-116.

引证文献10

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部